Fourteenth Finance Commission

Mount Logan Capital Inc. Announces Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Wednesday, March 22, 2023
Insurance, Asset management, Total revenue, Income Tax Act 1967, Fourteenth Finance Commission, MLC, Acquisition, Investment, Capital, Income Tax Act, Growth, EPS, ROE, NEO, Cryptocurrency, Bank, Security (finance), Reinsurance, Mount Logan, Ability

TORONTO, March 22, 2023 (GLOBE NEWSWIRE) -- Mount Logan Capital Inc. (NEO: MLC) (the “Company” or “Mount Logan”) announced today its financial results for the fourth quarter and full year ended December 31, 2022. All amounts are stated in United States dollars, unless otherwise indicated.

Key Points: 
  • Invested an additional $4.0 million into OCIF through the Company’s wholly-owned subsidiary Mount Logan Management LLC (“ML Management”).
  • Ted Goldthorpe, Chief Executive Officer and Chairman of Mount Logan stated, “We are excited about the progress made in 2022 as our strategic positioning of Mount Logan across the asset management and insurance solutions verticals produces results.
  • Basic Earnings per share (“EPS”) was $0.82 for fiscal 2022, a decrease of $0.73 from $1.55 for fiscal 2021.
  • Adjusted basic EPS was $0.57 for fiscal 2022, a decrease of $1.20 from $1.77 for fiscal 2021.

Yunkang Group Announces First Interim Results Since Listing, Net Profit Rises 50% to RMB234 Million

Retrieved on: 
Friday, August 12, 2022
People, City, Outline, Laboratory, Health, ICL, Precision medicine, Fourteenth Finance Commission, Hematology, Population, Social change, Growth, Policy, National Economic Protectionism Association, Infection, Hospital, Frost, Pharmacogenomics, Molecular biology, Hospital Insurance and Diagnostic Services Act, Government, Mass spectrometry, Republic, Neoplasm, Immunoassay, Marketing, Patient, COVID-19, Biotechnology, Awareness, CAGR, Lists of diseases, Pathology, Physician, Solution, PCR, Pharmaceutical industry, Medical imaging, Medical device, Group

Gross profit also increased by 68.6% to RMB651.1 million compared with the same period last year, and net profit rose by 50.0% to RMB234.4 million, establishing a new high within the same responding period.

Key Points: 
  • Gross profit also increased by 68.6% to RMB651.1 million compared with the same period last year, and net profit rose by 50.0% to RMB234.4 million, establishing a new high within the same responding period.
  • Diagnostic testing services for medical institution alliances mainly assists leading hospitals in establishing on-site diagnosis centers covering four main types (i.e.
  • Revenue from this segment rose by 166.2% to RMB650.7 million as at the Reporting Period.
  • As of 30 June 2022, the semi-annual average revenue of the on-site diagnostic centers was RMB1.9 million, compared with a full-year average revenue of RMB2.2 million in 2021.